Kathy Wedell, mother to Isaac, is Action Duchenne's new Campaigns Officer "On World Duchenne Awareness Day I’m delighted to announce that …
Action Duchenne are Delighted to Announce Our New Campaigns Officer: KathyRead More
Action Duchenne invites the participation of the Becker muscular dystrophy community in November!
On Friday 10 November 2017, the first day of our new and extended international conference will be dedicated to new horizons in pre-clinical research …
NICE Consultation on Guidelines for Suspected Neurological Conditions
NICE (the National Institute for Health and Care Excellence) have released for consultation, a new set of draft guidelines for healthcare …
NICE Consultation on Guidelines for Suspected Neurological ConditionsRead More
Pharmaceutical Companies Working in Duchenne Report Q2 Financial Results and Provide Business Updates
A number of pharmaceutical and biotech companies working in the field of Duchenne muscular dystrophy, have recently reported their 2nd quarter …
Portrait of Duchenne – Ravi’s good life
In the seventh interview in the “Portrait of Duchenne” series, our Canadian partners, La Force talked with Ravi Mehta at the Action …
Test with the Potential to More Reliably Screen for Duchenne in Newborns is Developed
Researchers at Cardiff University, in collaboration with biotechnology company PerkinElmer, have created a more reliable test to screen newborn babies …
Test with the Potential to More Reliably Screen for Duchenne in Newborns is DevelopedRead More
Mitobridge’s Potential Treatment for Duchenne Advances into Clinical Development
Mitobridge, Inc., a pioneer in the discovery and development of products that improve mitochondrial function, today announces a key milestone with the …
Mitobridge’s Potential Treatment for Duchenne Advances into Clinical DevelopmentRead More
Worldwide licence for new drug SOMO266 as SOM Biotech expands to the United States
The med-tech biopharmaceutical company, SOM Biotech, has granted a licence agreement with Corino Therapeutics Inc. for its first product SOMO266 for …
Worldwide licence for new drug SOMO266 as SOM Biotech expands to the United StatesRead More
Northern Ireland – ‘My Healthcare Passport’
A new study has started at Queen’s University Belfast. They are looking for young people aged 16-24 with a life-limiting condition and who …
Give your feedback to Summit in their Utrophin modulator patient/family survey
Summit are looking for feedback from caregivers and patients themselves in their commitment to working alongside patients, their families …
Give your feedback to Summit in their Utrophin modulator patient/family surveyRead More
Parity of esteem for people affected by neurological conditions – new report from the Neurological Alliance
The likelihood of having a comorbid mental health condition is higher for neurology patients than for the long-term conditions patient population …
Portrait of Duchenne – edasalonexent
In the fifth interview of the series “Portrait of Duchenne”, our Canadian partners La Fondation La Force talked with Joanne …
